Albany Molecular Research Inc., of Albany, N.Y., said its board adopted a shareholders rights plan, designed to enhance the board's ability to protect shareholder interests and to ensure that shareholders receive fair treatment in the event of a coercive takeover attempt.
Allos Therapeutics Inc., of Westminster, Colo., said updated Phase II results from a trial of RSR13 (efaproxiral) in locally advanced, unresectable non-small-cell lung cancer showed a showed a median survival rate of 20.6 months, a one-year survival rate of 67 percent and two-year survival of 37 percent. The study was in 52 patients and response-rate data were compiled on 44 patients who reached the two-month follow-up. The regimen included thoracic radiation therapy following induction chemotherapy. Allos said the results compare favorably to the 13-month median survival for the same regimen without RSR13. Allos said it plans to begin a Phase III study of RSR13 in Stage III non-small-cell lung cancer in the fourth quarter.
Cyntellect Inc., of San Diego, a research and development spin-off of Oncosis Inc., said that Oncosis received a Small Business Innovation Research grant to develop drug discovery applications on its Laser Enabled Analysis and Processing technology platform. LEAP is a laser-based platform designed to analyze and process living cells in a high-throughput manner. Cyntellect has announced the receipt of three new grant awards in the past two months, providing about $500,000 in new funding to support development of its LEAP platform.
DepoMed Inc., of Menlo Park, Calif., said that on Sept. 17 it received notice from the American Stock Exchange that the company's plan to regain compliance with AMEX listing standards was accepted and AMEX granted DepoMed an extension until January 2004 to regain compliance with those standards. Failure to regain compliance could result in DepoMed being delisted from AMEX. DepoMed's stock (AMEX:DMI) fell 35 cents Friday, or 10.5 percent, to close at $3.
Lipid Sciences Inc., of Pleasanton, Calif., said it voluntarily paused its Phase I trials to review the safety protocol following a transitory adverse reaction in a study participant. The trial is testing the safety of the company's plasma delipidation process, which is designed to remove lipids from plasma without disrupting protein function. The trial in Australia consists of 10 healthy volunteers.
Neugenesis Corp., of San Carlos, Calif., and Novozymes A/S, of Bagsvaerd, Denmark, began a joint research project to develop new methods to produce antibodies. It combines Neugenesis' technology in monoclonal antibodies with Novozymes' expertise in gene technology. The deal includes an option to form a broader partnership if the early work is successful.
SuperGen Inc., of Dublin, Calif., said that data from a clinical study of decitabine was to be presented Friday at the Leukemia 2002 - Towards the Cure Conference in Miami. The study, conducted at the M.D. Anderson Cancer Center in Houston, enrolled 50 patients with relapsed, refractory or poor prognosis hematological malignancies. SuperGen said low-dose decitabine showed promising activity with a relatively low degree of toxicity. Several Phase II studies in various groups of leukemias will follow, it said.
Transition Therapeutics Inc., of Toronto, said it received approval to begin a dose-escalating Phase I human trial in the UK of its Islet Neogenesis Therapy, which has been demonstrated in preclinical studies to be effective at stimulating the body to regenerate insulin-producing cells and at reducing diabetic symptoms. Transition expects to begin dosing patients by early October and the trial should be complete by early 2003.
Transkaryotic Therapies Inc., of Cambridge, Mass., said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee postponed meetings scheduled Thursday and Friday that were going to be held to review TKT's Replagal enzyme replacement therapy and Cambridge, Mass.-based Genzyme Corp.'s Fabrazyme, both being developed for Fabry's disease and both already approved in Europe. TKT said the postponement was due to administrative reasons at the FDA, and that the meetings are expected to be rescheduled for later this year. TKT's stock (NASDAQ:TKTX) fell $2.69 Friday to close at $30.31, and Genzyme shares (NASDAQ:GENZ) fell 34 cents to close at $21.42.